We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SIBIA Neurosciences (SIBI) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (457)7/21/1999 12:39:00 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 579
No, when Lilly took the option, it became their game. Just depends on how strong the trend toward significance was and what the dose response data actually says about the potential.

Program is now well-funded by Lilly, 1553A results coming this quarter. If the 1553 results are negative or "grey", then SIBI turns into a plain old bargain (VGCC/pain, caspase, patents and licenses, BMY/Novartis/Lilly), instead of a potential skyrocket with short fuse.